HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

The Path Forward in Breast Cancer Research

October 5th 2017

AR-Targeted Therapy and Immunotherapy for TNBC

October 5th 2017

Role of Neoadjuvant Platinum-Based Therapy for TNBC

October 5th 2017

PARP Inhibitors for BRCA-Associated TNBC

October 5th 2017

HER2+ Breast Cancer: Neratinib Patient Selection

October 5th 2017

Breast Cancer: Dual HER2-Targeted Adjuvant Therapy

October 5th 2017

Adjuvant Therapy for ER+/HER2+ Breast Cancer

October 5th 2017

Post-Adjuvant Therapy for HER2+ Breast Cancer

October 5th 2017

Neoadjuvant PI3 Kinase Inhibitors for HR+ Breast Cancer

October 5th 2017

Fulvestrant in the Era of CDK4/6 Inhibitors for HR+ mBC

October 5th 2017

Abemaciclib With Hormone Therapy for HR+ mBC

October 5th 2017

Differences Among CDK4/6 Inhibitors in HR+ mBC

October 5th 2017

Efficacy of CDK4/6 Inhibitors in HR+ mBC

October 5th 2017

Biomarkers for CDK4/6 Inhibitors in HR+ mBC

October 5th 2017

CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

October 5th 2017

HR+ Breast Cancer: Updated Results From MONARCH Trials

October 2nd 2017

Abemaciclib's Value in Treating HR+ Breast Cancer

October 2nd 2017

HR+ Breast Cancer: Pooled Analysis From MONARCH 2 and 3

October 2nd 2017

HR+ Breast Cancer: Resistance to Primary Therapy

October 2nd 2017

Factors in Deciding Treatment for HR+ Breast Cancer

October 2nd 2017